A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, 60-Week, Phase II Clinical Trial of Three Re-Purposed Medications in Moderate Severity Parkinson’s Disease
- Rowe, Dominic (Primary Chief Investigator)
- Gan, Richard (Research Coordinator)
Project: Research